Search results
Spotlight Therapeutics’ cell-specific in vivo gene editing platform, TAGE, takes center stage
Nature· 3 days agoWhile CRISPR-based therapeutics are showing proof-of-concept in the clinic, in vivo gene editing with cell-type specificity remains a major hurdle for the field. San Francisco Bay area–based ...
Driving the future of CAR-T cell therapies
Nature· 3 days agoUsing a multipronged strategy, Celyad is driving the development of next-generation chimeric antigen receptor-T cell-based therapies to treat cancer.
PTBP1 protects Y RNA from cleavage leading to its apoptosis-specific degradation - Cell Death ...
Nature· 3 days agoSome RNAs such as 28S rRNA, U1 small nuclear RNA (snRNA), and Y RNAs are known to be cleaved during apoptosis. The underlying mechanism, functions, and biological significance of RNA degradation ...
